GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Fulgent Genetics Inc (MEX:FLGT) » Definitions » COGS-to-Revenue

Fulgent Genetics (MEX:FLGT) COGS-to-Revenue : 0.66 (As of Mar. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Fulgent Genetics COGS-to-Revenue?

Fulgent Genetics's Cost of Goods Sold for the three months ended in Mar. 2024 was MXN703 Mil. Its Revenue for the three months ended in Mar. 2024 was MXN1,070 Mil.

Fulgent Genetics's COGS to Revenue for the three months ended in Mar. 2024 was 0.66.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Fulgent Genetics's Gross Margin % for the three months ended in Mar. 2024 was 34.28%.


Fulgent Genetics COGS-to-Revenue Historical Data

The historical data trend for Fulgent Genetics's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fulgent Genetics COGS-to-Revenue Chart

Fulgent Genetics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
COGS-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.43 0.21 0.22 0.41 0.64

Fulgent Genetics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.72 0.70 0.53 0.64 0.66

Fulgent Genetics COGS-to-Revenue Calculation

Fulgent Genetics's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=3136.111 / 4909.173
=0.64

Fulgent Genetics's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=703.366 / 1070.21
=0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Fulgent Genetics  (MEX:FLGT) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Fulgent Genetics's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 703.366 / 1070.21
=34.28 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Fulgent Genetics COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Fulgent Genetics's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Fulgent Genetics (MEX:FLGT) Business Description

Traded in Other Exchanges
Address
4978 Santa Anita Avenue, Temple City, CA, USA, 91780
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. Genetic testing offers the possibility of early identification of a disease or a genetic predisposition to disease and enhanced disease treatment and prognosis. Fulgent's product portfolio includes Genes & Panels, Known Mutation, Genomic Testing, Hereditary Cancer, Carrier Screening, Tumor Profiling, and Sequencing Service. Its customers are categorized as Insurance; Institutional, which includes hospitals, medical institutions, laboratories, governmental bodies, municipalities, and large corporations; and Patients. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

Fulgent Genetics (MEX:FLGT) Headlines

From GuruFocus

Insider Alert: An Insider Just Sold Fulgent Genetics Inc Shares

By GuruFocus Research GuruFocus Editor 05-21-2023